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Cardiac troponins I and T (cTnI anti cTnT) have been established as definite markers 
for cell injury allowing risk stratification in patients with acute coronary syndromes 
(ACS). Elevations of cTnI and cTnT in patients with unstable angina (UA) are associated 
with increased risk for severe cardiac events. These markers are also of great interest 
for identifying groups of patients for whom the selected treatments will be the most 
beneficial. In the recent years, the acute-phase reactant C—reactive protein (CRP) has 
been found to be elevated across the clinical spectrum of atherosclerotic coronary 
artery diseases. Furthermore, increased concentrations of CRP are predictive for 
higher risk for long-term cardiovascular morbidity and mortality in ACS patients. 
B-type natriuretic peptide (BNP), the active neurohormone and the remaining part of 
the prohormone, NT-proBNP can be measured by immunoassay. The BNP related 
peptides are secreted info circulation from the ventricular muscle in response to 
myocyte stretch. BNP and proBNP have been proposed as markers for the severity of 
heart failure. Recently, it has been demonstrated that a single measurement of NT-
proBNP improved the early risk stratification of ACS patients with or without ST 
segment elevation. In these patients, NT-proBNP levels seem independently associated 
with prognosis. 
These three types of biomarkers assess different pathophysiological mechanisms in 
myocardial ischemia: elevation of cTnI or cTnT indicate myocyte necrosis, CRP is a 
marker of inflammation, and BNP or NT-proBNP are elevated in response to left vent-
icular overload. Recent data suggest that simultaneous assessment of these three 
markers would allow clinicians to stratify risk among ACS patients more effectively 
than cardiac troponins alone. 
